| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vivo |
- In allergen-induced bronchial obstruction guinea pig models: After being sensitized and challenged with allergens, guinea pigs treated with Androsin (10 mg/kg, intravenous injection) showed a significant reduction in bronchial obstruction compared to the vehicle-treated control group. The bronchoconstrictive response induced by allergens was notably inhibited by Androsin.
- In PAF (platelet-activating factor)-induced bronchial obstruction guinea pig models: Intravenous administration of Androsin (10 mg/kg) prior to PAF challenge significantly attenuated PAF-triggered bronchial obstruction. The degree of bronchial narrowing in Androsin-treated guinea pigs was much lower than that in the control group [1] |
|---|---|
| Animal Protocol |
- Allergen-induced bronchial obstruction experiment:
1. Guinea pigs were first sensitized with allergens (specific allergen not specified in the literature) to establish an allergic asthma-like state, following a preset sensitization schedule. 2. After sensitization, guinea pigs were randomly divided into two groups: the Androsin group and the vehicle control group. 3. Androsin was dissolved in an appropriate vehicle (vehicle type not specified) and administered to guinea pigs via intravenous injection at a dose of 10 mg/kg; the control group received the same volume of vehicle only. 4. A certain time after drug administration (exact interval not specified), all guinea pigs were challenged with the same allergen used for sensitization to induce bronchial obstruction. 5. The degree of bronchial obstruction was monitored and recorded using relevant respiratory function detection methods (specific detection method not specified) [1] - PAF-induced bronchial obstruction experiment: 1. Guinea pigs were randomly assigned to two groups: the Androsin group and the vehicle control group. 2. Androsin was prepared in a suitable vehicle (vehicle type not specified) and given to guinea pigs via intravenous injection at 10 mg/kg; the control group received an equal volume of vehicle. 3. After a predetermined time (exact time not specified) post-drug administration, guinea pigs in both groups were injected with PAF to induce bronchial obstruction. 4. Respiratory parameters related to bronchial function were measured to evaluate the degree of bronchial obstruction [1] |
| References | |
| Additional Infomation |
According to reports, antler extract is found in deer antler, spruce, and other organisms with relevant data.
- antler extract is an active ingredient isolated from the medicinal plant Coptis chinensis. It can prevent bronchial obstruction caused by allergens and platelet-activating factor (PAF), which is the key mechanism of the anti-asthmatic effect of Coptis chinensis [1] |
| Molecular Formula |
C15H20O8
|
|---|---|
| Molecular Weight |
328.3145
|
| Exact Mass |
328.115
|
| CAS # |
531-28-2
|
| PubChem CID |
164648
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
568.3±50.0 °C at 760 mmHg
|
| Melting Point |
218-220ºC
|
| Flash Point |
210.6±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.593
|
| LogP |
-1.09
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
403
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(=O)C1=CC(=C(C=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC
|
| InChi Key |
QUOZWMJFTQUXON-UXXRCYHCSA-N
|
| InChi Code |
InChI=1S/C15H20O8/c1-7(17)8-3-4-9(10(5-8)21-2)22-15-14(20)13(19)12(18)11(6-16)23-15/h3-5,11-16,18-20H,6H2,1-2H3/t11-,12-,13+,14-,15-/m1/s1
|
| Chemical Name |
1-[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~380.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0459 mL | 15.2295 mL | 30.4590 mL | |
| 5 mM | 0.6092 mL | 3.0459 mL | 6.0918 mL | |
| 10 mM | 0.3046 mL | 1.5230 mL | 3.0459 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
